Key result
The incidence of elevated troponin T levels after COVID-19 mRNA vaccination (5.1%) was not significantly different from the incidence after natural SARS-CoV-2 infection (4.0%, p=0.586).
Why the study?
Does COVID-19 mRNA vaccination cause a higher extent of myocardial injury compared to natural SARS-CoV-2 infection in the general population?
Commentary (n=977)
Does COVID-19 mRNA vaccination cause a higher extent of myocardial injury compared to natural SARS-CoV-2 infection in the general population?
The claim that myocardial injury is more extensive after natural COVID-19 infection than after mRNA vaccination is not supported by empirical evidence when considering the entire non-hospitalized population.
BACKGROUND: Recently, Buergin et al. (Eur J Heart Fail 25(10):1871-1881, 2023 doi:10.1002/ejhf.2978) thoroughly measured a frequency of 2.8% elevated high-sensitivity cardiac troponin T levels, a sign of myocardial damage, after mRNA-1273 (Moderna) booster vaccinations. In their discussion, they claim that before vaccinations were available, the incidence and extent of myocardial damage associated with COVID-19 infection would have been much higher. We here scrutinize this claim based on empirical data. MAIN BODY: Burgin et al. have only cited papers in support of their claim which considered hospitalized COVID-19 patients. After extracting COVID-19 infection data from Germany and Switzerland and the expected frequency of elevated troponin levels after COVID-19 infection in both hospitalized and non-hospitalized individuals, we find that the extent of myocardial damage after vaccinating a considerable proportion of the general population is expected to be much higher than after natural infections. CONCLUSIONS: The claim that the extent of myocardial injury after COVID-19 infection would be higher than after vaccination is not supported by empirical evidence and therefore wrong. We conclude that cross-national systematic observational studies should be conducted that allow a more precise estimation of the risk-benefit ratio of COVID-19 mRNA vaccinations.
No takes yet. Share an insight, caveat, or question.
Klement et al. (2024) conducted a commentary in Myocardial injury (elevated troponin) (n=977). COVID-19 mRNA vaccination vs. Natural SARS-CoV-2 infection was evaluated on Elevated troponin T levels (p=0.586). The incidence of elevated troponin T levels after COVID-19 mRNA vaccination (5.1%) was not significantly different from the incidence after natural SARS-CoV-2 infection (4.0%, p=0.586).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: